Given the reproducible association of GC-C activating mutations with IBD, it is important to consider that chronic activation of the GC-C pathway by ligand treatment may activate inflammasomes and trigger IBD-like immunopathology (255). The gene discussed is GUCY2C; the disease is irritable bowel syndrome.